OrbiMed Capital LLC and OrbiMed Advisors LLC report that they no longer own any shares of SI-BONE, Inc. common stock. As of the event date of 12/31/2025, each reporting person discloses beneficial ownership of 0 shares, representing 0.0% of SI-BONE’s common stock.
They report no sole or shared voting or dispositive power over any SI-BONE shares and confirm they now own 5 percent or less of the class. The firms state the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.
Positive
None.
Negative
None.
Insights
OrbiMed now reports 0% ownership of SI-BONE, ending its status as a large shareholder.
OrbiMed Advisors LLC and OrbiMed Capital LLC disclose beneficial ownership of 0 SI-BONE common shares, or 0.0% of the class, with no voting or dispositive power. This formally ends their role as a reportable large institutional holder in the company.
The filing also notes that OrbiMed historically held the stock in the ordinary course of business and not to influence control. Actual implications depend on when and how prior positions were reduced, which is not detailed here, but the update clarifies that OrbiMed is no longer an equity stakeholder of record.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
SI-BONE, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
825704109
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
825704109
1
Names of Reporting Persons
OrbiMed Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP No.
825704109
1
Names of Reporting Persons
OrbiMed Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
SI-BONE, Inc.
(b)
Address of issuer's principal executive offices:
471 El Camino Real, Suite 101, Santa Clara, CA 95050
Item 2.
(a)
Name of person filing:
OrbiMed Capital LLC
OrbiMed Advisors LLC
(b)
Address or principal business office or, if none, residence:
601 Lexington Avenue, 54th Floor
New York, NY 10022
(c)
Citizenship:
Please refer to Item 4 on each cover sheet for each filing person.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
825704109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 0
(b)
Percent of class:
OrbiMed Advisors LLC: 0.0%
OrbiMed Capital LLC: 0.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 0
(ii) Shared power to vote or to direct the vote:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 0
(iii) Sole power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 0
(iv) Shared power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Reporting Persons hold 0.0% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What does OrbiMed’s amended Schedule 13G/A say about its SI-BONE (SIBN) ownership?
The amended filing states OrbiMed Advisors LLC and OrbiMed Capital LLC now beneficially own 0 shares of SI-BONE common stock, representing 0.0% of the class, ending their status as significant institutional shareholders in the company.
How many SI-BONE (SIBN) shares does OrbiMed currently report owning?
OrbiMed Advisors LLC and OrbiMed Capital LLC each report beneficial ownership of 0 SI-BONE common shares. They also disclose no sole or shared voting or dispositive power over any SI-BONE stock as of the stated event date.
What percentage of SI-BONE (SIBN) does OrbiMed report owning in this 13G/A?
Both OrbiMed Advisors LLC and OrbiMed Capital LLC report beneficial ownership of 0.0% of SI-BONE’s common stock. This confirms they now hold 5 percent or less of the class and are no longer reportable large shareholders.
Why was this Schedule 13G/A amendment filed for SI-BONE (SIBN)?
The amendment updates OrbiMed’s position, showing that OrbiMed Advisors LLC and OrbiMed Capital LLC now beneficially own 0 SI-BONE shares, or 0.0% of the class, and have no voting or dispositive power over the stock as of 12/31/2025.
Did OrbiMed indicate any intent to influence control of SI-BONE (SIBN)?
The certification states the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing SI-BONE’s control, nor in connection with any transaction having that control-related purpose or effect.
Who signed the amended SI-BONE (SIBN) Schedule 13G/A for OrbiMed?
The amendment is signed by Carl L. Gordon as a Member of OrbiMed entities. He certifies, after reasonable inquiry, that the information in the statement is true, complete, and correct as of the signature date 02/17/2026.
